Different definitions of atopic dermatitis: impact on prevalence estimates and associated risk factors.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
accepted:
28
02
2019
pubmed:
2
3
2019
medline:
13
3
2021
entrez:
2
3
2019
Statut:
ppublish
Résumé
There is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD), and no uniform clinical definition. To investigate to what extent operational definitions of AD cause fluctuation in the prevalence estimates and the associated risk factors. We first reviewed the operational definitions of AD used in the literature. We then tested the impact of the choice of the most common definitions of 'cases' and 'controls' on AD prevalence estimates and associated risk factors (including filaggrin mutations) among children aged 5 years in two population-based birth cohorts: the Manchester Asthma and Allergy Study (MAAS) and Asthma in Ashford. Model performance was measured by the percentage of children within an area of clinical indecision (defined as having a posterior probability of AD between 25% and 60%). We identified 59 different definitions of AD across 45 reviewed studies. Of those, we chose four common 'case' definitions and two definitions of 'controls'. The prevalence estimates using different case definitions ranged between 22% and 33% in MAAS, and between 12% and 22% in Ashford. The area of clinical indecision ranged from 32% to 44% in MAAS and from 9% to 29% in Ashford. Depending on the case definition used, the associations with filaggrin mutations varied, with odds ratios (95% confidence intervals) ranging from 1·8 (1·1-2·9) to 2·2 (1·3-3·7) in MAAS and 1·7 (0·8-3·7) to 2·3 (1·2-4·5) in Ashford. Associations with filaggrin mutations also differed when using the same 'case' definition but different definitions of 'controls'. Use of different definitions of AD results in substantial differences in prevalence estimates, the performance of prediction models and association with risk factors. What's already known about this topic? There is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD) and no uniform clinical definition. This results in different definitions utilized in AD studies, raising concerns on the generalizability of the results and comparability across different studies. What does this study add? This study has shown that different definitions of 'cases' and 'controls' have major impacts upon prevalence estimates and associations with risk factors, including genetics, in two population-based birth cohorts. These findings suggest the importance of developing a consensus on AD definitions of both 'controls' and 'cases' to minimize biases in studies.
Sections du résumé
BACKGROUND
There is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD), and no uniform clinical definition.
OBJECTIVES
To investigate to what extent operational definitions of AD cause fluctuation in the prevalence estimates and the associated risk factors.
METHODS
We first reviewed the operational definitions of AD used in the literature. We then tested the impact of the choice of the most common definitions of 'cases' and 'controls' on AD prevalence estimates and associated risk factors (including filaggrin mutations) among children aged 5 years in two population-based birth cohorts: the Manchester Asthma and Allergy Study (MAAS) and Asthma in Ashford. Model performance was measured by the percentage of children within an area of clinical indecision (defined as having a posterior probability of AD between 25% and 60%).
RESULTS
We identified 59 different definitions of AD across 45 reviewed studies. Of those, we chose four common 'case' definitions and two definitions of 'controls'. The prevalence estimates using different case definitions ranged between 22% and 33% in MAAS, and between 12% and 22% in Ashford. The area of clinical indecision ranged from 32% to 44% in MAAS and from 9% to 29% in Ashford. Depending on the case definition used, the associations with filaggrin mutations varied, with odds ratios (95% confidence intervals) ranging from 1·8 (1·1-2·9) to 2·2 (1·3-3·7) in MAAS and 1·7 (0·8-3·7) to 2·3 (1·2-4·5) in Ashford. Associations with filaggrin mutations also differed when using the same 'case' definition but different definitions of 'controls'.
CONCLUSIONS
Use of different definitions of AD results in substantial differences in prevalence estimates, the performance of prediction models and association with risk factors. What's already known about this topic? There is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD) and no uniform clinical definition. This results in different definitions utilized in AD studies, raising concerns on the generalizability of the results and comparability across different studies. What does this study add? This study has shown that different definitions of 'cases' and 'controls' have major impacts upon prevalence estimates and associations with risk factors, including genetics, in two population-based birth cohorts. These findings suggest the importance of developing a consensus on AD definitions of both 'controls' and 'cases' to minimize biases in studies.
Identifiants
pubmed: 30822368
doi: 10.1111/bjd.17853
pmc: PMC6916614
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1272-1279Subventions
Organisme : Medical Research Council
ID : G0601361
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K002449/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K002449/2
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
J Invest Dermatol. 2015 Jan;135(1):24-30
pubmed: 25186228
Pediatr Allergy Immunol. 2002;13(s15):32-7
pubmed: 12688622
Br J Dermatol. 2008 Apr;158(4):754-65
pubmed: 18241277
Allergy. 2013 Apr;68(4):498-506
pubmed: 23452057
Allergy. 2018 Apr;73(4):923-931
pubmed: 29150853
Dermatol Clin. 2017 Jul;35(3):275-281
pubmed: 28577796
Allergy. 2016 Oct;71(10):1480-5
pubmed: 27392131
J Allergy Clin Immunol. 2014 Oct;134(4):769-79
pubmed: 25282559
Am J Clin Dermatol. 2018 Feb;19(1):15-22
pubmed: 28624959
J Eur Acad Dermatol Venereol. 2016 May;30(5):729-47
pubmed: 27004560
Br J Dermatol. 1994 Sep;131(3):406-16
pubmed: 7918017
J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125-38
pubmed: 9893196
PLoS Med. 2008 Jun 24;5(6):e131
pubmed: 18578563
Clin Exp Allergy. 2010 Dec;40(12):1776-84
pubmed: 21059120
Br J Dermatol. 2005 Apr;152(4):735-41
pubmed: 15840106
Allergy. 2016 Oct;71(10):1379-80
pubmed: 27624706
J Allergy Clin Immunol. 2014 Oct;134(4):867-875.e1
pubmed: 25282568
Nat Genet. 2011 Dec 25;44(2):187-92
pubmed: 22197932
Eur Respir J. 2010 Jul;36(1):48-56
pubmed: 20032011
J Allergy Clin Immunol. 2008 Apr;121(4):872-7.e9
pubmed: 18325573
JAMA Pediatr. 2017 Jul 1;171(7):655-662
pubmed: 28531273
Eur Respir J. 1995 Mar;8(3):483-91
pubmed: 7789502
PLoS Med. 2014 Oct 21;11(10):e1001748
pubmed: 25335105
Pediatr Allergy Immunol. 2010 Nov;21(7):1052-8
pubmed: 20735756
N Engl J Med. 2011 Oct 6;365(14):1315-27
pubmed: 21991953
Br J Dermatol. 2018 Jun;178(6):1280-1287
pubmed: 29336013
J Allergy Clin Immunol. 2012 Jul;130(1):137-44
pubmed: 22424882
Allergy. 2009 Dec;64(12):1758-65
pubmed: 19839980
Thorax. 2004 Oct;59(10):855-61
pubmed: 15454651
J Allergy Clin Immunol. 2009 Jun;123(6):1361-70.e7
pubmed: 19501237
Br J Dermatol. 1994 Sep;131(3):383-96
pubmed: 7918015
Br J Dermatol. 1998 Mar;138(3):436-42
pubmed: 9580796
Br J Dermatol. 1994 Sep;131(3):397-405
pubmed: 7918016
Thorax. 2015 Aug;70(8):799-801
pubmed: 25805205
J Allergy Clin Immunol. 2018 Mar;141(3):964-971
pubmed: 29129583
J Am Acad Dermatol. 2016 Oct;75(4):681-687.e11
pubmed: 27544489
J Allergy Clin Immunol. 2015 Nov;136(5):1265-7
pubmed: 26549637
Am J Respir Crit Care Med. 2010 Jun 1;181(11):1200-6
pubmed: 20167852
Allergy. 2017 Dec;72(12):2026-2030
pubmed: 28605026
Allergy. 2001 Sep;56(9):813-24
pubmed: 11551246
J Allergy Clin Immunol. 2017 Apr;139(4S):S58-S64
pubmed: 28390478